Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology
|
Buy Now
Malignant - How Bad Policy and Bad Evidence Harm People with Cancer (Hardcover)
Loot Price: R798
Discovery Miles 7 980
|
|
Malignant - How Bad Policy and Bad Evidence Harm People with Cancer (Hardcover)
Expected to ship within 12 - 17 working days
|
How hype, money, and bias can mislead the public into thinking that
many worthless or unproven treatments are effective. Each week,
people read about new and exciting cancer drugs. Some of these
drugs are truly transformative, offering major improvements in how
long patients live or how they feel-but what is often missing from
the popular narrative is that, far too often, these new drugs have
marginal or minimal benefits. Some are even harmful. In Malignant,
hematologist-oncologist Dr. Vinayak K. Prasad writes about the many
sobering examples of how patients are too often failed by cancer
policy and by how oncology is practiced. Throughout this work,
Prasad illuminates deceptive practices which * promote novel cancer
therapies long before credible data are available to support such
treatment; and * exaggerate the potential benefits of new
therapies, many of which cost thousands and in some cases hundreds
of thousands of dollars. Prasad then critiques the financial
conflicts of interest that pervade the oncology field, the
pharmaceutical industry, and the US Food and Drug administration.
This is a book about how the actions of human beings-our policies,
our standards of evidence, and our drug regulation-incentivize the
pursuit of marginal or unproven therapies at lofty and
unsustainable prices. Prasad takes us through how cancer trials are
conducted, how drugs come to market, and how pricing decisions are
made, asking how we can ensure that more cancer drugs deliver both
greater benefit and a lower price. Ultimately, Prasad says, * more
cancer clinical trials should measure outcomes that actually matter
to people with cancer; * patients on those trials should look more
like actual global citizens; * we need drug regulators to raise,
not perpetually lower, the bar for approval; and * we need unbiased
patient advocates and experts. This well-written, opinionated, and
engaging book explains what we can do differently to make serious
and sustained progress against cancer-and how we can avoid
repeating the policy and practice mistakes of the past.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.